Eli Lilly Corp. Stock

Eli Lilly continues its remarkable market ascension as the pharmaceutical giant capitalizes on rival Novo Nordisk's struggles. The Indianapolis-based company has seen its weight loss medication

Eli Lilly's stock showed surprising stability, with minimal movement despite significant pipeline developments. The pharmaceutical giant received positive news as the European Medicines Agency (EMA)

Eli Lilly has acquired gene therapy specialist Verve Therapeutics for $1.3 billion, marking a significant move into genetic medicine as the biotech sector emerges from a two-year slump. The

Eli Lilly shares could face pressure after Donald Trump reinforced his intention to impose tariffs on imported pharmaceuticals. The Republican president plans to implement duties of "25% or higher"

Eli Lilly has intensified its legal campaign against pharmacies producing unauthorized versions of its weight-loss medication tirzepatide. The pharmaceutical giant filed lawsuits against Strive

Eli Lilly's experimental drug Lepodisiran has delivered impressive results in Phase 2 clinical trials, reducing a genetic risk factor for heart disease by nearly 94 percent. The drug targets

Eli Lilly's stock has demonstrated remarkable resilience this year, gaining approximately 6% while Danish competitor Novo Nordisk faced significant losses. This divergence in performance reflects a